NAII NATURAL ALTERNATIVES INTERNATIONAL INC
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 787253 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.1%
TTM net income YoY-92.6%
TTM EPS YoY-89.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin4.4%
Operating margin-16.3%
Net margin-17.2%
FCF margin-5.0%
EBITDA margin-12.8%
Returns
ROE-39.4%
ROA-16.9%
ROIC (approx.)-30.3%
Asset turnover0.98x
Leverage & solvency
Liabilities / assets58.8%
Debt / equity0.23x
Current ratio1.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $28.12M | $34.51M | $35.48M | $34.80M | $37.73M | $33.87M | $28.77M | $34.08M |
| Cost of revenue | $26.86M | $32.78M | $35.10M | $32.30M | $33.33M | $30.33M | $26.94M | $32.41M |
| Gross profit | $1.27M | $1.73M | $383,000 | $2.49M | $4.40M | $3.54M | $1.83M | $1.67M |
| SG&A expense | $3.85M | — | $4.40M | $4.34M | $4.11M | — | $3.93M | $4.45M |
| Operating income | -$2.58M | -$13.18M | -$4.01M | -$1.85M | $284,000 | -$1.94M | -$2.10M | -$2.78M |
| Pretax income | -$2.74M | -$13.49M | -$4.24M | -$2.33M | -$199,000 | -$2.82M | -$2.64M | -$2.87M |
| Income tax | -$265,000 | $46,000 | $68,000 | $224,000 | $92,000 | $4.40M | -$456,000 | -$675,000 |
| Net income | -$2.48M | -$13.54M | -$4.31M | -$2.55M | -$291,000 | -$7.22M | -$2.19M | -$2.19M |
| EBITDA | -$1.54M | -$11.99M | -$2.82M | -$681,000 | $1.45M | -$784,000 | -$961,000 | -$1.65M |
| EPS (basic) | -0.41 | — | -0.72 | -0.42 | -0.05 | — | -0.37 | -0.37 |
| EPS (diluted) | -0.41 | — | -0.72 | -0.42 | -0.05 | — | -0.37 | -0.37 |
| Weighted avg. shares (diluted) | 6.07M | — | 6.03M | 6.01M | 6.01M | — | 5.94M | 5.92M |
| Banking | ||||||||
| Net interest income | -$560,000 | -$466,000 | -$270,000 | -$224,000 | -$226,000 | -$212,000 | -$246,000 | -$278,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $6.49M | $7.39M | $9.20M | $7.39M | $7.74M | $12.32M | $10.61M | $8.66M |
| Receivables | $12.43M | $20.65M | $20.59M | $20.65M | $18.91M | $14.64M | $11.65M | $16.90M |
| Inventory | $28.16M | $30.75M | $29.93M | $30.75M | $30.65M | $24.87M | $26.99M | $23.04M |
| Current assets | $54.30M | $65.43M | $63.99M | $65.43M | $65.05M | $59.28M | $58.52M | $58.55M |
| PP&E, net | $35.33M | $35.60M | $50.81M | $35.60M | $50.79M | $50.89M | $50.56M | $50.94M |
| Total assets | $114.53M | $126.45M | $154.88M | $126.45M | $156.94M | $151.94M | $154.94M | $156.13M |
| Current liabilities | $39.58M | $37.72M | $39.12M | $37.72M | $33.90M | $28.80M | $23.31M | $21.65M |
| Long-term debt | $10.80M | $10.90M | — | — | — | — | — | — |
| Total debt | $10.80M | $10.90M | — | — | — | — | — | — |
| Total liabilities | $67.34M | $76.49M | $91.77M | $76.49M | $87.92M | $83.51M | $78.33M | $76.99M |
| Shareholders' equity | $47.19M | $49.96M | $63.11M | $49.96M | $69.02M | $68.43M | $76.62M | $79.14M |
| Net debt | $4.32M | $3.51M | — | — | — | — | — | — |
| Shares outstanding | 6.26M | 6.27M | 6.28M | 6.27M | 6.18M | 6.18M | 6.18M | 6.20M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.20M | -$1.07M | $2.50M | -$6.33M | -$4.02M | $3.35M | $5.99M | $37,000 |
| Capital expenditure | $264,000 | $637,000 | $1.10M | $934,000 | $1.03M | $1.46M | $802,000 | $1.06M |
| Free cash flow | $932,000 | -$1.70M | $1.40M | -$7.26M | -$5.05M | $1.89M | $5.19M | -$1.02M |
| Investing cash flow | -$264,000 | -$637,000 | -$1.10M | -$934,000 | -$1.03M | -$1.46M | -$802,000 | -$1.06M |
| Financing cash flow | -$1.66M | -$19,000 | $4.04M | $3.27M | $472,000 | -$176,000 | -$3.24M | -$474,000 |
| Depreciation & amortization | $1.04M | $1.18M | $1.19M | $1.17M | $1.17M | $1.16M | $1.14M | $1.13M |
| Stock-based compensation | $91,000 | $108,000 | $140,000 | $178,000 | $177,000 | $179,000 | $245,000 | $277,000 |
| Share buybacks | $3,000 | $2,000 | $82,000 | $0 | $5,000 | $2,000 | $168,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.